跳至主要内容
临床试验/DRKS00008974
DRKS00008974已完成未知

Individualized short-term therapy for adolescents impaired by ADHD despite previous routine care treatment (ESCAdol) - a randomized controlled trial within the consortium ‘ESCAlife’ - ESCAadol

niversitätsklinikum Würzburg0 个研究点目标入组 157 人开始时间: 2015年12月28日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
157

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomized controlled study
盲法
Blinded (masking used)

入排标准

年龄范围
12 Years 至 17 Years(—)
性别
All

入选标准

  • ADHD according to DSM-5 criteria; diagnosis established by clinician-rated ADHD-Checklist (DCL-ADHS)
  • - patient has been in ADHD routine care for a minimum of 6 months
  • -no sufficient benefit from previous interventions developed for the treatment of ADHD children or ADHD adults (insufficient benefit defined as significant impairment by ADHD and/or co-morbid symptoms: CGI-S > 4)
  • - patients and primary caregiver speak sufficient German

排除标准

  • - IQ < 80
  • - comorbidity: pervasive developmental disorder, schizophrenia, bipolar disorder, severe depressive episode
  • - need for inpatient treatment
  • - after TAU-Phase co-treatment including: a) intensive psychotherapies on a biweekly or more intense basis or b) medication which is not constant or not licensed for the treatment of ADHD and co-morbid conditions

研究者

发起方
niversitätsklinikum Würzburg

相似试验